Project Grant HT94252510229
Award Date
6/15/25
Completion Date
6/14/29
Dollars Obligated
$7M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98195, USA
Similar Awards
This $1,535,039 federal Project Grant award from the Defense Health Agency's Military Medical Research and Development Program (CFDA 12.420) supports research conducted by Wake Forest University Health Sciences (WFUHS) to study how the breast tissue microbiota regulates immune checkpoint blockade therapy responsiveness in triple-negative breast cancer. The research aims to advance scientific understanding and develop new treatment approaches for this aggressive form of breast cancer that...
The University of Massachusetts Amherst was awarded a $557,247 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund research from February 1, 2023 to January 31, 2026 to develop intracellular bacterial delivery of vaccine antigens to establish T-cell antitumor immunity in triple-negative breast cancer. The Military Medical Research and Development program supports innovative medical research with...
This $2,542,500.00 federal Project Grant award was issued by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to support research on therapeutic targeting of the tumor microenvironment in triple-negative breast cancer patients at high risk of relapse and preclinical models of lung metastases. The grant was awarded to Weill Medical College of Cornell University, a prominent academic medical institution, with a performance period from May 15, 2025...
This Defense Health Agency Project Grant award of $1,204,899 to Duke University, with a period of performance from January 1, 2024 to December 31, 2027, supports targeted vaccination research to treat and prevent endocrine-resistant ER+ breast cancer. The project aims to develop new treatments by targeting common resistance genes and neoepitope mutations. This grant is funded through the Department of Defense's Military Medical Research and Development program (CFDA 12.420), which supports...
The Defense Health Agency awarded a $784,602 Project Grant to Dana-Farber Cancer Institute, Inc. (doing business as Dfci) under the Military Medical Research and Development program (CFDA 12.420). The grant will support research from January 2023 to January 2026 to develop next-generation immunotherapy for breast cancer by turning breast cancer cells against themselves. The Military Medical Research and Development program aims to transform military and public health through innovative medical...
This $1,173,081 federal Project Grant award, issued by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports the Fred Hutchinson Cancer Center's research to prevent recurrence of triple negative breast cancer. The project, titled "Targeting Epidermal Plasticity to Prevent Triple Negative Breast Cancer Recurrence," will be conducted over a 4-year period from April 2025 to March 2029. The research aims to develop innovative...
The U.S. Department of Defense's Defense Health Agency has awarded a $466,234 Project Grant to the University of Queensland in Australia to conduct "PROOF-OF-CONCEPT STUDIES FOR A NOVEL IMMUNOTHERAPY FOR TRIPLE-NEGATIVE BREAST CANCER AND COMPANION DIAGNOSTIC." This research grant, funded through the Military Medical Research and Development program (CFDA 12.420), aims to develop innovative treatments and diagnostic tools to improve care for military service members, veterans, and their...
The federal Project Grant award provides $1,151,250.00 to Texas A&M University System Health Science Center to develop a unique small molecule for triple-negative breast cancer. The grant is funded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research initiatives to improve health outcomes for military service members, veterans, and the public. The award period runs from July 1, 2024 to June 30, 2027....
The U.S. Department of Defense, through the Military Medical Research and Development (CFDA 12.420) federal grant program, awarded a $505,071 Project Grant to The University of Texas MD Anderson Cancer Center. The grant, awarded on February 15, 2025, supports the "Discovery of Noncanonical Antigens in Triple-Negative Breast Cancer for Development of Novel T Cell Therapies" research project. The funding will enable the cancer center to conduct advanced biomedical research focused on...
This $1,251,230.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program supports breast cancer research at the University of Wisconsin - Madison. The award will fund a clinical trial over a 4-year period from June 2025 to June 2029, involving a Breakthrough Award - Funding Level 3 with a Partnering Principal Investigator option. The research aims to transform healthcare for military service members and the broader public...